Neurologic, neuropathologic, and neurochemical effects of prolonged administration of phenylisopropylhydrazine (JB 516), phenylisobutylhydrazine (JB 835), and other monoamine oxidase inhibitors.
D002492:Central Nervous System Depressants; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009420:Nervous System / Q000494:pharmacology*; D009461:Neurologic Manifestations; D009488:Neurosciences; D010659:Phenylhydrazines
D002492:Central Nervous System Depressants; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D010659:Phenylhydrazines; C005433:methylphenylpropylhydrazine; C047131:phenylisobutylhydrazine; C084776:pheniprazine
HYDRAZINES/pharmacology; MONOAMINE OXIDASE INHIBITORS/pharmacology; NERVOUS SYSTEM/pharmacology; NEUROLOGIC MANIFESTATIONS/experimental